Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells

Graphical Abstract

Highlights

- Pseudoviral SARS-CoV-2 induces the acid sphingomyelinase/ceramide system
- Inhibition of acid sphingomyelinase prevents cellular infection with SARS-CoV-2
- Neutralization of ceramide in vitro blocks infection with pseudoviral SARS-CoV-2

Authors

Alexander Carpinteiro,
Michael J. Edwards, Markus Hoffmann, ..., Syed A. Ahmad, Klaus Fassbender, Erich Gulbins

Correspondence
erich.gulbins@uni-due.de

In Brief

Carpinteiro et al. report in a preclinical study that the acid sphingomyelinase/ceramide system is involved in SARS-CoV-2 infections. Functional inhibition of the acid sphingomyelinase/ceramide system with antidepressants reduces infection with authentic or pseudoviral SARS-CoV-2 in vitro. Amitriptyline prevents ex vivo infection of freshly isolated nasal epithelial cells with pseudoviral SARS-CoV-2.
SUMMARY
The acid sphingomyelinase/ceramide system plays an important role in bacterial and viral infections. Here, we report that either pharmacological inhibition of acid sphingomyelinase with amitriptyline, imipramine, fluoxetine, sertraline, escitalopram, or maprotiline or genetic downregulation of the enzyme prevents infection of cultured cells or freshly isolated human nasal epithelial cells with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or vesicular stomatitis virus (VSV) pseudoviral particles (pp-VSV) presenting SARS-CoV-2 spike protein (pp-VSV-SARS-CoV-2 spike), a bona fide system mimicking SARS-CoV-2 infection. Infection activates acid sphingomyelinase and triggers a release of ceramide on the cell surface. Neutralization or consumption of surface ceramide reduces infection with pp-VSV-SARS-CoV-2 spike. Treating volunteers with a low dose of amitriptyline prevents infection of freshly isolated nasal epithelial cells with pp-VSV-SARS-CoV-2 spike. The data justify clinical studies investigating whether amitriptyline, a safe drug used clinically for almost 60 years, or other antidepressants that functionally block acid sphingomyelinase prevent SARS-CoV-2 infection.

INTRODUCTION
Infections with a novel member of the Coronaviridae family were reported in late 2019 in Wuhan, China. The virus was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Subsequently, the virus spread globally and is responsible for the coronavirus disease 2019 (COVID-19) pandemic. Infection with SARS-CoV-2 often results in mild respiratory tract disease, but a substantial number of patients also experience severe symptoms and pneumonia, and ~70% of these critically ill patients require intensive care and ventilator treatment, with a mortality rate of 62%. Even when the large number of only mildly affected patients are included, the mortality rates are higher than those associated with seasonal influenza.

Cellular infection with SARS-CoV-2 is initiated by the binding of the surface unit S1 of the viral spike glycoprotein to its cellular receptor angiotensin-converting enzyme 2 (ACE2), resulting in cleavage of the viral spike protein by the activity of transmembrane serine protease 2 (TMPRSS2) or cathepsin L and in viral entry. Although the binding of the virus to its receptor has
been elucidated in detail, the changes that occur in the host cell membrane during viral processing and entry require definition. Membrane changes that mediate viral entry may be a very promising target for preventing the infection.

Previous studies have used replication-deficient vesicular stomatitis virus (VSV) pseudoviral particles (pp-VSV) presenting SARS-CoV-2 spike protein (pp-VSV-SARS-CoV-2 spike) on their surface. Studies have shown that these particles accurately reflect key aspects of the entry of coronavirus into host cells. These particles were previously shown to bind to ACE2 for infectious entry, and entry was inhibited by anti-ACE2 antibodies. Thus, these particles are a bona fide model for studying the events of SARS-CoV-2 entry.

We have previously shown that acid sphingomyelinase and ceramide play an important role in receptor signaling and infection biology. Acid sphingomyelinase (EC 3.1.4.12, sphingomyelin phosphodiesterase; optimal pH 5.0) is a glycoprotein that functions as a lysosomal hydrolase, catalyzing the degradation of sphingomyelin to phosphorylcholine and ceramide. Acid sphingomyelinase is present in lysosomes, but because these compartments are constantly recycling to the plasma membrane, it can also be found on the cell surface. The activity of acid sphingomyelinase on the cell surface results in the formation of ceramide in the outer leaflet of the cell membrane. The generation of ceramide molecules within the outer leaflet alters the biophysical properties of the plasma membrane because the very hydrophobic ceramide molecules spontaneously associate with each other to form small ceramide-enriched membrane domains that fuse and form large, highly hydrophobic, tightly packed, gel-like ceramide-enriched membrane domains. In addition, ceramide has been shown to directly bind to a variety of proteins, including cathepsin D, phospholipase A2, ceramide-activated protein serine/threonine phosphatases (CAPP), protein kinase C isoforms, and microtubule-associated proteins 1A/1B light chain LC3B-II.

Many antidepressants functionally inhibit acid sphingomyelinase activity. These cationic amphiphilic drugs indirectly inhibit acid sphingomyelinase activity by displacing the enzyme from lysosomal membranes, in particular intralysosomal vesicles, thereby releasing the enzyme into the lysosomal lumen and causing its partial degradation.

We have previously shown that rhinovirus infections activate acid sphingomyelinase and lead to the formation of ceramide and ceramide-enriched membrane domains. Amitriptyline, sertraline, and other functional inhibitors of acid sphingomyelinase activity (FIASMA) inhibit cellular infection with rhinovirus. Similar observations have been made regarding infections with Ebola virus, demonstrating that amitriptyline and other FIASMA inhibit infection with Ebola virus in vitro.

Because some antidepressants are widely used in clinical practice and have a very favorable safety profile, we investigated whether these drugs could be repurposed to treat or prevent infections with SARS-CoV-2.

Our results show that acid sphingomyelinase is activated within 20 to 30 min after treatment with pp-VSV-SARS-CoV-2 spike; this activation results in the release of ceramide in the outer leaflet of the plasma membrane. In cell culture models, pharmacological or genetic inhibition of acid sphingomyelinase activity or neutralization of surface ceramide prevents the infection of cells with authentic SARS-CoV-2 and pp-VSV-SARS-CoV-2 spike. The addition of exogenous C16 ceramide or acid sphingomyelinase reconstituted the infection with pp-VSV-SARS-CoV-2 spike in cells that had been treated with antidepressants or transfected with short hairpin RNA (shRNA) targeting acid sphingomyelinase. We involved human volunteers in tests of the FIASMA amitriptyline, a safe antidepressant that has been used clinically since 1962. Infection of freshly isolated nasal epithelial cells from volunteers who had been treated with a single dose of 0.5 mg/kg amitriptyline showed almost complete inhibition of the infection of nasal epithelial cells with pp-VSV-SARS-CoV-2 spike particles, an inhibition that lasted for at least 24 h.

RESULTS

Amitriptyline Inhibits SARS-CoV-2 Infections

To determine whether acid sphingomyelinase can be targeted to prevent the infection of cells with SARS-CoV-2, we treated Vero cells with the FIASMA amitriptyline or left the cells untreated. We then exposed the cells to pp-VSV-SARS-CoV-2 spike particles and determined infection by measuring the expression of virus-encoded enhanced green fluorescent protein (eGFP) in the infected cells. The results indicate efficient infection of untreated Vero cells with pp-VSV-SARS-CoV-2 spike (Figures 1A and S1). Treating the cells with 5, 10, 20, or 25 μM amitriptyline reduced the infection rate with pp-VSV-SARS-CoV-2 spike by as much as 90%, which was measured as the reduction of the expression of the reporter gene (Figures 1A and S1). Infection of epithelial cells with SARS-CoV-2 has been shown to induce an upregulation of ACE2 expression. We used upregulation of ACE2 expression in Vero cells as an additional readout for infection and for the effects of amitriptyline. Our findings showed that infecting Vero cells with pp-VSV-SARS-CoV-2 spike increased ACE2 expression in Vero cells; this increase was dose-dependently prevented by pretreatment with 10 or 25 μM amitriptyline (Figure 1B). The infection of cells with pp-VSV-G (VSV particles that express the glycoprotein of VSV), which served as a control, was not affected by amitriptyline (Figure 1B).

Fluorescein isothiocyanate (FITC)-Annexin V staining, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays, and staining for the actin cytoskeleton (Figures 1C, 1D, and S2) detected no cytotoxic effects associated with a 24-h treatment with amitriptyline.

Next, we determined whether amitriptyline also affects the infection of human Caco-2 cells with authentic SARS-CoV-2. Amitriptyline-pretreated Caco-2 cells were infected with SARS-CoV-2, and the replication of SARS-CoV-2 was monitored by quantitative real-time RT-PCR by using two separate primer sets and a plaque assay. The results showed that amitriptyline also reduced the infection of human cells with SARS-CoV-2 by approximately 90% (Figure 2).

pp-VSV-SARS-CoV-2 Infection Requires Activation of Acid Sphingomyelinase and Release of Ceramide

The results of these studies suggested that acid sphingomyelinase serves an important function in SARS-CoV-2 infection. To confirm the role of acid sphingomyelinase in infection
with SARS-CoV-2 independent of pharmacological inhibition, we used shRNA-mediated suppression of the expression of acid sphingomyelinase in Caco-2 cells. We confirmed the downregulation of acid sphingomyelinase by measuring the activity of the enzyme in lysates of uninfected cells (Figure 3A). The results showed that genetic downregulation of acid sphingomyelinase prevented infection with pp-VSV-SARS-CoV-2 spike (Figure 3A). Control shRNA constructs had no effect on cellular infection with pp-VSV-SARS-CoV-2 spike (Figure 3A).

We next investigated whether infection with pp-VSV-SARS-CoV-2 spike activates the acid sphingomyelinase/ceramide system. The results showed that treating Vero cells with pp-VSV-SARS-CoV-2 spike resulted in rapid activation of acid sphingomyelinase and a concomitant release of ceramide (Figures 3B and 4A).

In contrast, treating Vero cells with pp-VSV lacking SARS-CoV-2 spike or with pp-VSV-G particles did not result in the activation of acid sphingomyelinase or in a release of ceramide (Figures 3B and 4A), a finding indicating that the activation of acid sphingomyelinase and the release of ceramide are specifically induced by the spike protein. Pretreatment of the cells with SARS-CoV-2 independent of pharmacological inhibition, we used shRNA-mediated suppression of the expression of acid sphingomyelinase in Caco-2 cells. We confirmed the downregulation of acid sphingomyelinase by measuring the activity of the enzyme in lysates of uninfected cells (Figure 3A). The results showed that genetic downregulation of acid sphingomyelinase prevented infection with pp-VSV-SARS-CoV-2 spike (Figure 3A). Control shRNA constructs had no effect on cellular infection with pp-VSV-SARS-CoV-2 spike. We further tested whether neutral sphingomyelinase may also be involved in cellular infection with SARS-CoV-2. To this end, we transfected Caco-2 cells with shRNA targeting neutral sphingomyelinase 2 and control shRNA. Transfection reduced neutral sphingomyelinase activity by approximately 60% but had no effect on cellular infection with pp-VSV-SARS-CoV-2 spike (Figure 3A).

We next investigated whether infection with pp-VSV-SARS-CoV-2 spike activates the acid sphingomyelinase/ceramide system. The results showed that treating Vero cells with pp-VSV-SARS-CoV-2 spike resulted in rapid activation of acid sphingomyelinase and a concomitant release of ceramide (Figures 3B and 4A).

In contrast, treating Vero cells with pp-VSV lacking SARS-CoV-2 spike or with pp-VSV-G particles did not result in the activation of acid sphingomyelinase or in a release of ceramide (Figures 3B and 4A), a finding indicating that the activation of acid sphingomyelinase and the release of ceramide are specifically induced by the spike protein. Pretreatment of the cells with SARS-CoV-2 independent of pharmacological inhibition, we used shRNA-mediated suppression of the expression of acid sphingomyelinase in Caco-2 cells. We confirmed the downregulation of acid sphingomyelinase by measuring the activity of the enzyme in lysates of uninfected cells (Figure 3A). The results showed that genetic downregulation of acid sphingomyelinase prevented infection with pp-VSV-SARS-CoV-2 spike (Figure 3A). Control shRNA constructs had no effect on cellular infection with pp-VSV-SARS-CoV-2 spike. We further tested whether neutral sphingomyelinase may also be involved in cellular infection with SARS-CoV-2. To this end, we transfected Caco-2 cells with shRNA targeting neutral sphingomyelinase 2 and control shRNA. Transfection reduced neutral sphingomyelinase activity by approximately 60% but had no effect on cellular infection with pp-VSV-SARS-CoV-2 spike (Figure 3A).
10, 20, or 25 µM amitriptyline prevented the activation of acid sphingomyelinase and the release of ceramide upon infection with pp-VSV-SARS-CoV-2 spike for 30 min (Figures 3B and 4A). Controls showed that amitriptyline reduced both the constitutive and the viral-induced activity of acid sphingomyelinase (Figure 3B).

Treating Vero cells with neutralizing antibodies to spike or with recombinant ACE2 protein prevented the activation of acid sphingomyelinase and the release of ceramide upon infection with pp-VSV-SARS-CoV-2 spike (Figures 3B and 4A), a finding that indicated that the interaction of spike with ACE2 mediates the activation of acid sphingomyelinase.

To confirm the formation of ceramide and to determine whether ceramide is released in the plasma membrane after infection, we stained Vero cells prior to and after infection with pp-VSV-SARS-CoV-2 spike (Figures 5A and 5C). Controls confirmed that amitriptyline or the application of anti-ceramide antibodies or neutral ceramidase prevented the infection of freshly isolated nasal epithelial cells with pp-VSV-SARS-CoV-2 spike (Figure 5B). Reconstitution of ceramide in the drug-treated Vero cells by the addition of exogenous C16 ceramide restored infection with the pp-VSV-SARS-CoV-2 spike (Figure 5C) and did not induce cell death (Figure S3).

**Surface Ceramide Is Required for pp-VSV-SARS-CoV-2 Infection**

Neutralization or consumption of surface ceramide by treatment of cells with two separate monoclonal anti-ceramide IgM, i.e., clone S58-9, and a monoclonal anti-ceramide IgG, or neutral ceramidase, respectively, prevented the infection with pp-VSV-SARS-CoV-2 spike (Figure 5A) in a dose-dependent manner, a finding indicating that surface ceramide is required for viral entry.

Many antidepressants functionally inhibit acid sphingomyelinase activity, very likely by interfering with the binding of the protein to lysosomal membranes; this interference results in the release of the enzyme from these membranes and in the degradation of the protein.20–25 Therefore, we tested whether several other antidepressants, namely imipramine, desipramine, fluoxetine, sertraline, escitalopram, and maprotiline, also inhibit the infection of Vero cells with pp-VSV-SARS-CoV-2 spike. The results showed that all of these drugs at concentrations between 5 µM and 35 µM inhibited acid sphingomyelinase activity (Figure 5B), prevented the entry of pp-VSV-SARS-CoV-2 spike (Figure 5C), and prevented the upregulation of surface ACE2 as marker for the infection (Figure 5D), whereas these drugs exerted no effect on the infection of cells with pp-VSV-G (Figure 5C). Reconstitution of ceramide in the drug-treated Vero cells by the addition of exogenous C16 ceramide restored infection with pp-VSV-SARS-CoV-2 spike (Figure 5C) and did not induce cell death (Figure S3).

**Ex vivo Infection of Freshly Isolated Human Nasal Epithelial Cells with pp-VSV-SARS-CoV-2 Spike Is Prevented by Amitriptyline, Anti-ceramide Antibodies, or Neutral Ceramidase**

Next, we treated freshly isolated human nasal epithelial cells with amitriptyline, anti-ceramide antibodies, or neutral ceramidase before or upon infection with pp-VSV-SARS-CoV-2 spike. A 60-min pretreatment with 10 µM amitriptyline or the application of anti-ceramide antibodies or neutral ceramidase prevented the infection of freshly isolated nasal epithelial cells with pp-VSV-SARS-CoV-2 spike, as determined by viral uptake (Figure 6A). Reconstitution of ceramide in amitriptyline-treated nasal epithelial cells by the addition of exogenous C16 ceramide restored infection with the pp-VSV-SARS-CoV-2 spike (Figure 6A). Controls demonstrated that amitriptyline reduced the
Amitriptyline Administered In Vivo Prevents SARS-CoV-2 Infection of Freshly Isolated Human Nasal Epithelial Cells

Although these findings demonstrate that the infection of Vero cells, Caco-2 cells, and freshly isolated human nasal epithelial cells with pp-VSV-SARS-CoV-2 spike and authentic SARS-CoV-2 can be prevented by treatment with amitriptyline or other antidepressants, with anti-ceramide antibodies, or with neutral ceramidase, they do not demonstrate that clinically used doses of amitriptyline also block infection with pp-VSV-SARS-CoV-2 spike. To mimic as closely as possible the in vivo effect of amitriptyline on infection with pp-VSV-SARS-CoV-2 spike, we treated volunteers with a single oral dose of 0.5 mg/kg amitriptyline. This is a low dose (37.5 mg for a 70-kg volunteer) with no severe adverse effects. We isolated nasal epithelial cells before and 1.5 h and 24 h after the oral administration of amitriptyline and infected these cells by exposing them to pp-VSV-SARS-CoV-2 spike for 60 min. Amitriptyline reduced the activity of acid sphingomyelinase in nasal epithelial cells isolated from the volunteers 1.5 h and 24 h after oral administration. The activity of the enzyme remained reduced for at least 60 min ex vivo (Figure 7A). Thus, this protocol allowed us to test the effect of amitriptyline applied in vivo on the infection of nasal epithelial cells with pp-VSV-SARS-CoV-2 spike ex vivo. The experiments demonstrated that administration of a single oral dose of amitriptyline to volunteers prevented infection of nasal epithelial cells with pp-VSV-SARS-CoV-2 spike (Figures 7B and 7C). The protective effect of amitriptyline administered in vivo against infection with pp-VSV-SARS-CoV-2 spike lasted for at least 24 h (Figure 7B). Infection of cells from amitriptyline-treated volunteers was restored by the addition of exogenous C16 ceramide (Figure 7B).

**DISCUSSION**

In summary, our findings indicate that SARS-CoV-2 activates the acid sphingomyelinase/ceramide pathway and uses this activity of acid sphingomyelinase in nasal epithelial cells (Figure 6B).
pathway for infection. Pharmacological or genetic inhibition of acid sphingomyelase activity prevents infection with authentic SARS-CoV-2 virus or pp-VSV-SARS-CoV-2 spike particles in cell culture models and in freshly isolated human nasal epithelial cells from volunteers treated with amitriptyline and infected ex vivo.

Amitriptyline and other drugs with a similar structure and properties have been clinically used for many years (since 1962) to treat patients with depressive disorders. In the volunteer studies, we used a low dose of amitriptyline, i.e., 0.5 mg/kg, which is lower than the dose usually used to treat patients with major depression (75–150 mg/day, i.e., approximately 1–2 mg/kg). At this dose, the drug has only mild effects, such as dry mucosa and tiredness. However, at higher dosages (higher than 100 mg/day, twice the dose we used or higher), amitriptyline and many other antidepressants may induce a cardiac QT elongation as a possible (but rare) adverse effect. QT elongation can result in cardiac arrhythmia and serious cardiac adverse effects. Thus, it may be advisable to perform an electrocardiogram (ECG) before the first administration of amitriptyline or any of the other FIASMAs used here to exclude a pre-existing QT elongation. Amitriptyline and other antidepressants acting as FIASMAs exert no known adverse effects on the immune system.

Our studies demonstrate that even low dosages of amitriptyline provide long-lasting and very efficient protection against infection. Our findings also indicate that other drugs, such as imipramine, desipramine, fluoxetine, sertraline, escitalopram, and maprotiline, with concentrations similar to that of amitriptyline prevent infection with pp-VSV-SARS-CoV-2 spike.

Our studies are strongly supported by a recently pre-printed study that showed a marked beneficial effect of antidepressants on the clinical course of COVID-19. Hospitalized patients receiving antidepressants had a much better outcome, determined as decreased medical necessity of intubation or death, than patients receiving no antidepressants. Best results were
obtained with venlafaxine, fluoxetine, escitalopram, and mirtazapine, drugs that were also shown in the present study to inhibit acid sphingomyelinase and ceramide release upon pp-VSV-SARS-CoV-2 spike infection. It is important to note that the dose of antidepressants used in this retrospective study was not optimized. Amitriptyline was used at a medium dose of 26 mg/day, which is a rather low dose. Amitriptyline is often used at these low dosages for sedation and not as an antidepressant, whereas other drugs such as fluoxetine and escitalopram are always used as antidepressants and applied at higher dosages. Furthermore, fluoxetine also inhibits SARS-CoV-2 replication, an effect that was not investigated in the present study, because the pseudoviral particles do not replicate.

Amitriptyline and many other antidepressants are weak bases that are protonated in lysosomes and thereby trapped in lysosomes, but they also localize in acidic subcompartments of the cell membrane. Because of their physicochemical properties (for instance for amitriptyline: high lipophilicity and weak basicity; logP = 4.92, acid dissociation constant pKa = 9.4; https://go.drugbank.com/), these drugs accumulate in acidic intracellular compartments. This accumulation leads to a high tissue concentration and accordingly to a high volume of distribution (for instance for amitriptyline: distribution volume Vd = 16 L/kg; https://go.drugbank.com/). Thus, high tissue concentrations of these drugs can be detected in all organs. In fact, the highest uptake of amitriptyline among all tissues with a lung/blood concentration gradient of approximately 50 is found in the lungs of mice and rats. In humans, even higher concentration gradients have been found between the lung and blood. Because of the particularly high accumulation in the lung, the antiviral in vitro concentrations (up to 25 μM) that we found to be effective are likely to be achieved with conventional oral therapy of amitriptyline. We also expect a considerably longer elimination half-life of amitriptyline in lung tissue than in blood because of the high concentration of these drugs in deep compartments, such as lysosomes.

The organic ring system of amitriptyline and other FIASMAs may bind to the lipid membrane, whereas the protonated tertiary amine displaces acid sphingomyelinase from lysosomal membranes or from the plasma membrane within acidic subdomains. Thus, these weak bases do not directly inhibit acid sphingomyelinase activity but rather functionally inhibit it. This mode of action...
also explains why antidepressants do not completely inhibit acid sphingomyelinase activity and do not induce severe adverse effects in clinical use.

In addition, our studies indicate that the administration of anti-ceramide antibodies or neutral ceramidase also protects against SARS-CoV-2 infections. Anti-ceramide antibodies and neutral ceramidase are not approved for clinical use but could be easily tested for systemic or local adverse effects before the treatment of SARS-CoV-2 infections. Furthermore, both anti-ceramide antibodies and neutral ceramidase could potentially be administered by inhalation or as a nasal spray to prevent SARS-CoV-2 infections.

The molecular mechanisms of how ceramide mediates the infection of epithelial cells with SARS-CoV-2 remain to be determined. Ceramide has been shown to directly activate several enzymes and to form large, highly hydrophobic ceramide-enriched membrane domains that serve to re-organize receptor and signaling molecules. It remains to be determined whether SARS-CoV-2 also induces these platforms and whether ceramide and/or these platforms are required for the internalization or activation of TMPRSS2 and cathepsin L that mediate the processing of spike required for fusion with the cell membrane.36

High ceramide levels have been linked with hypertension and obesity,37,38 two of the most important risk factors for the development of serious infections with SARS-CoV-2. It is tempting to speculate that the increased levels of ceramide associated with these diseases sensitize cells to infection with SARS-CoV-2 and thereby contribute to the development of serious infections.

COVID-19. We hope that our study stimulates further studies that support or refute the clinical use of antidepressants for the prevention or treatment of SARS-CoV-2 infections.

Limitations of Study

The findings were generated from experimental in vitro model systems. Infections were performed ex vivo, and experiments in animal models are required to confirm the data in vivo. Although we showed that infection of human epithelial cells and different human cell lines with SARS-CoV-2 and pp-VSV-SARS-CoV-2 spike particles is significantly reduced by treatment with several antidepressants and genetic inhibition of the acid sphingomyelinase, this does not necessarily reflect the clinical situation in COVID-19. Clinical data/studies are required to define the clinical use of antidepressants for the treatment of COVID-19. Clinical studies are also required to elucidate how the acid sphingomyelinase and ceramide are involved in infection.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead Contact
  - Materials Availability
  - Data and Code Availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Human subjects
  - Primary cells

Figure 6. Infection of Freshly Isolated Human Nasal Epithelial Cells Is Prevented by Ex Vivo Treatment with AT, Anti-Cer Antibodies, or neut. CDase

(A) Freshly isolated human nasal epithelial cells were infected with pp-VSV-SARS-CoV-2 spike for 60 min. Anti-Cer antibodies (IgM or IgG) or neut. CDase were co-applied with the virus. AT (10 μM) was applied for 60 min before the infection and was also present during the infection. All of these treatments blocked the infection of freshly isolated human nasal epithelial cells with pp-VSV-SARS-CoV-2 spike. Control IgM, IgG, or 0.9% NaCl (solvent for AT) exerted no effect. Ceramide was reconstituted in AT-treated nasal epithelial cells with 10 μM C16-Cer; this reconstitution restored the infection of the cells with pp-VSV-SARS-CoV-2 spike. (B) AT reduced ASM activity in nasal epithelial cells upon infection. Shown are the means ± SD of 6 (A) or 5 (B) independent experiments. ***p < 0.001; ANOVA, followed by post hoc Student’s t tests.
In Vivo Administration of AT Prevents Infection of Nasal Epithelial Cells with pp-VSV-SARS-CoV-2 Spike

Volunteers were orally treated with 0.5 mg/kg AT. Nasal epithelial cells were isolated from volunteers before and 1.5 h and 24 h after administration of AT. (A) Activity of ASM was determined by measurement of the consumption of [14C]sphingomyelin in aliquots of freshly isolated nasal epithelial cells or after an additional 1-h culture ex vivo. (B) After isolation, nasal epithelial cells were infected for 1 h, with pp-VSV-SARS-CoV-2 spike and washed. The expression of EGFP was determined after 24 h in at least 500 epithelial cells per sample in randomly chosen microscopic fields. Ceramide in nasal epithelial cells isolated from volunteers who had taken AT was reconstituted with 10 μM C16-Cer. This reconstitution restored the infection of the cells with pp-VSV-SARS-CoV-2 spike. The percentage of infected nasal epithelial cells is displayed. (C) Shown is a typical result from 6 independent infection studies with nasal epithelial cells from volunteers before and after oral administration of AT. The bottom panel shows an over-exposed microphotograph to visualize all cells. Shown are the means ± SD from 6 volunteers. ***p < 0.001; ANOVA, followed by post hoc Student’s t tests.

- Cell lines
  - METHOD DETAILS
    - Pseudoviral particles
    - Infection of nasal epithelial cells
    - Ex vivo treatment of nasal epithelial cells
    - Infection of Vero lines
    - Flow cytometry of surface ACE2 as measurement for infection
    - Infection with SARS-CoV-2
    - Neutralization of ceramide

- FITC-Annexin V binding
- TUNEL studies
- Actin staining
- Genetic downregulation of sphingomyelinas
- Acid sphingomyelinas activity
- Neutral sphingomyelinas activity
- Measurement of ceramide
- Other antidepressans
- Ceramide reconstitution
- Flow cytometry of surface ceramide

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.xcrm.2020.100142.

ACKNOWLEDGMENTS

The study was supported by Deutsche Forschungsgemeinschaft, Germany, grants Gu-335-35/1 and GU-335-38/1 to Erich Gulbins and Federal Ministry of Science (BMBF), RAPID Consortium grant 01Kl1723D to Stefan Pöhlmann.

AUTHOR CONTRIBUTIONS

E.G. initiated the studies. E.G., M.J.E., A.C., B.G., S.A.A., J.K., Silke Walter, Sameer Patel, G.C.W., T.B., M.K., C.A., and K.F. contributed to the planning of the experiments. M.H. and Stefan Pöhlmann provided the pp-VSV-SARS-CoV-2 spike. S. Weigang, G.K., H.H., and P.A.L. performed and discussed the SARS-CoV-2 experiments. E.G., A.C., K.A.B., E.C., A.G., B.G., and K.S.L. performed the human studies. J.K., S.W., K.F., B.G., and E.G. determined the dosages of antidepressans. E.G. performed all other infection experiments and measurements of enzymes and ceramide. M.S., C.S., S.K., and B.W. contributed to the immune staining studies. All authors have read and commented on the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing financial interests.

Received: June 29, 2020
Revised: September 23, 2020
Accepted: October 22, 2020
Published: October 29, 2020

REFERENCES

1. Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., et al. (2020). A pneumonia outbreak associated with a novel coronavirus of probable bat origin. Nature 579, 270–273.
2. Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475–481.
3. World Health Organization. Coronavirus disease (COVID-19): similarities and differences with influenza. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza?gclid=EA1aQobCHzIz5b_0bem6QVnFvDTRlH1s1QwHEAAAYASAEgJomPD_BwE.
4. John Hopkins University. Mortality analyses. https://coronavirus.jhu.edu/data/mortality.
11. Gulbins, E., and Kolesnick, R. (2003). Raft ceramide in molecular medi-
10. Cell Reports Medicine
10. Grassmê, H., Jendrossek, V., Riehle, A., von K
12. Kolesnick, R.N., Gon˜i, F.M., and Alonso, A. (2000). Compartmentalization
15. Huwiler, A., Johansen, B., Skarstad, A., and Pfeilschifter, J. (2001). Cer-
14. Heinrich, M., Wickel, M., Schneider-Brachert, W., Sandberg, C., Gahr, J.,
13. Nurminen, T.A., Holopainen, J.M., Zhao, H., and Kinnunen, P.K.J. (2002).
16. Dobrowsky, R.T., and Hannun, Y.A. (1993). Ceramide-activated protein
18. Huwiler, A., Fabbro, D., and Pfeilschifter, J. (1998). Selective ceramide
17. M
19. Dany, M., Gencer, S., Nganga, R., Thomas, R.J., Oleinik, N., Baron, K.D.,
22. Kornhuber, J., Tripal, P., Reichel, M., Terfloth, L., Bleich, S., Wiltfang, J.,
23. Gulbins, E., Palmada, M., Reichel, M., Lüth, A., Böhmer, C., Amato, D.,
Muller, C.P., Tischbirek, C.H., Groemer, T.W., Tabatabai, G., et al. (2013). Acid sphingomyelinase-ceramide system mediates effects of anti-
depressant drugs. Nat. Med. 19, 934–938.
24. Gulbins, A., Schumacher, F., Becker, K.A., Wilker, B., Soddemann, M.,
Boldrin, F., Müller, C.P., Edwards, M.J., Goodman, M., Caldwell, C.C.,
et al. (2018). Antidepressants act by inducing autophagy controlled by sphingomyelin-ceramide. Mol. Psychiatry 23, 2324–2346.
25. Breiden, B., and Sandhoff, K. (2019). Emerging mechanisms of drug-
induced phospholipidosis. Biol. Chem. 401, 31–46.
26. Grassmê, H., Riehle, A., Wilker, B., and Gulbins, E. (2005). Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms. J. Biol. Chem. 280, 26256–26262.
27. Miller, M.E., Adhikary, S., Kolokolts, A.A., and Davey, R.A. (2012). Ebo-
lavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. J. Virol. 86, 7473–7483,
28. Ziegler, C.G.K., Allon, S.J., Nyquist, S.K., Mbanou, I.M., Miao, V.N., Tzoua-
nas, C.N., Cao, Y., Yousif, A.S., Bals, J., Hauser, B.M., et al. (2020). SARS-
CoV-2 receptor ACE2 is an Interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181, 1016–1035.e19.
29. Unterecker, S., Puhlmann, B., Kopf, J., Kittel-Schneider, S., Reif, A., and
Deckert, J. (2015). Increase of heart rate and QTc by Amtriptyline, but not by Venlafaxine, is correlated to serum concentration. J. Clin. Psycho-
pharmacol. 35, 460–463.
30. Hoertel, N., Sanchez Rico, M., Verrey, R., Beeker, N., Janonn, A.-S., Neu-
rav, A., Salamanca, E., Paris, N., Daniel, C., Gramfort, A., et al. (2020). As-
sociation between SSRI antidepressant use and reduced risk of intubation or death in hospitalized patients with coronavirus disease 2019: a multi-
center retrospective observational study. medRxiv. https://doi.org/10.1101/2020.07.09.2014339.t.
31. Zimmia, K., Kirschner, L., Hilpert, H., Seibel, J., and Bodem, J. (2020). The
serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2. bioRxiv. https://doi.org/10.1101/2020.06.14.150490,
32. Trapp, S., Rosania, G.R., Horobin, R.W., and Kornhuber, J. (2008). Quan-
titative modeling of selective lysosomal targeting for drug design. Eur. Bio-
phys. J. 37, 1317–1328.
33. Cassano, G.B., Sjöstrand, S.E., and Hansson, E. (1965). Distribution and fate of C-14-amitriptyline in mice and rats. Psychopharmacology (Berl.) 8, 1–11.
34. Hilberg, T., Merland, J., and Bjernboe, A. (1994). Postmortem release of amitriptyline from the lungs; a mechanism of postmortem drug redistribu-
tion. Forensic Sci. Int. 64, 47–55.
35. Bynum, N.D., Poklis, J.L., Gaffney-Kraft, M., Garside, D., and Ropero-
Miller, J.D. (2005). Postmortem distribution of tramadol, amitryptiline, and their metabolites in a suicidal overdose. J. Anal. Toxicol. 29, 401–406,
36. Matsuyama, S., Nagata, N., Shirato, K., Kawase, M., Takeda, M., and T-
guchii, F. (2010). Efficient activation of the severe acute respiratory syn-
drome coronavirus spike protein by the transmembrane protease TMPRSS2. J. Virol. 84, 12658–12664.
37. Yu, J., Pan, W., Shi, R., Yang, T., Li, Y., Yu, G., Bai, Y., Schuchman, E.H.,
He, X., and Zhang, G. (2015). Ceramide is upregulated and associated with mortality in patients with chronic heart failure. Can. J. Cardiol. 31, 357–363.
38. Smith, E.L., and Schuchman, E.H. (2008). The unexpected role of acid
sphingomyelinase in cell death and the pathophysiology of common dis-
esases. FASEB J. 22, 3419–3431.
39. Berger Rentsch, M., and Zimmer, G. (2011). A vesicular stomatitis virus re-
pli-con-based bioassay for the rapid and sensitive determination of multi-
species type I interferon. PLoS One 6, e25858.
40. Kleine-Weber, H., Elzayat, M.T., Wang, L., Graham, B.S., Müller, M.A.,
Drosten, C., Pöhlmann, S., and Hoffmann, M. (2019). Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization. J. Virol. 93, e01381-18.
## STAR★METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Antibodies          |        |            |
| Anti-VSV-G (I1, produced from CRL-2700 mouse hybridoma cells) | ATCC | Cat# CRL-2700; RRID: CVCL_G654 |
| Rabbit monoclonal anti-SARS-Cov-2 Spike 1 | Sino Biological | Cat# 40150-R-007; RRID: AB_2827979 |
| Mouse anti-ceramide IgM antibody clone S85-9 | Glycobiotech | Cat# MAB_0014 |
| Mouse monoclonal anti-ceramide IgG | Antibody Res. Corp. | Cat# 111583 |
| Cy3-coupled donkey anti-mouse IgM F(ab)2 fragment | Jackson ImmunoResearch | Cat# 715-166-020 |
| Goat anti-ACE2 antibody | R&D | Cat# AF933 |
| FITC-coupled donkey anti-goat antibody | Jackson ImmunoResearch | Cat# 705-096-147 |
| **Bacterial and Virus Strains** |        |            |
| SARS-CoV-2 (isolate Muc-IMB-1) | Bundeswehr Institute of Microbiology, Munich, Germany | Isolate Muc-IMB-1 |
| VSV*ΔG-Fluc | Laboratory of Stefan Pöhlmann, ref. | n/a |
| **Chemicals, Peptides, and Recombinant Proteins** |        |            |
| Recombinant human neutral ceramidase | R&D | Cat# 3557 AH |
| Recombinant ACE2 | Abcam | Cat# ab273687 |
| Recombinant acid sphingomyelinase | R&D | Cat# 5348-PD-010 |
| Amitriptyline, Tablets | Neuraxpharm | PZN 3343120 |
| Amitriptyline | Sigma-Aldrich | Cat# A8404 |
| Imipramine | Sigma-Aldrich | Cat# 10899 |
| Desipramine | Sigma-Aldrich | Cat# D3900 |
| Sertraline | Sigma-Aldrich | Cat# 56319 |
| Escitalopram | Sigma-Aldrich | Cat# E4786 |
| Maprotiline | Sigma-Aldrich | Cat# M9651 |
| Fluoxetine | Sigma-Aldrich | Cat# 56296-78-7 |
| C16-ceramide | Avanti Polar Lipids | Cat# 860516 |
| [14C]sphingomyelin | Perkin Elmer | Cat# NEC 663010UC |
| [32P]ATP | Hartmann Radiocemicals | Cat# SCP-501-150 |
| DAG kinase | ENZO | Cat# BML-SE100 |
| FITC-Annexin V | Roche | Cat#11 828 681 001 |
| Cell dissociation buffer | GIBCO | Cat#13151-014 |
| **Critical Commercial Assays** |        |            |
| TUNEL kit (in situ cell death detection kit TMR red) | Roche | Cat#12156792910 |
| **Experimental Models: Cell Lines** |        |            |
| Human nasal epithelial cells | Healthy volunteers | This study |
| Caco-2 (human colon epithelial cells) | ATCC | Cat# HTB-37; RRID CVCL_0025 |
| Vero (monkey kidney epithelial cells) | ATCC | Cat# CCL-81; RRID CVCL_0059 |
| HEK293T (human embryonic kidney cells) | DSMZ | Cat# ACC-635; RRID CVCL_0063 |
| **Oligonucleotides** |        |            |
| SRBR Green 1 fwd: GCCTCTTCTCGTCTCATCAC | Merck | n/a |

(Continued on next page)
RESOURCE AVAILABILITY

Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Erich Gulbins (erich.gulbins@uni-due.de).

Materials Availability
This study did not generate new unique reagents.

Data and Code Availability
The published article includes all datasets generated or analyzed during the study.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human subjects
Human nasal epithelial cells were obtained from 6 healthy volunteers, 4 women and 2 men. Their ages were 20, 21, 43, 48, 54, and 56. We did not observe any differences in infection between cells from women or men. Sample size was planned for the continuous variable difference in viral uptake and was based on two-sided Wilcoxon-Mann-Whitney tests using G*Power Version 3.1.7, University of Duesseldorfe, Germany. Nasal epithelial cells were obtained from all subjects prior and after oral administration of amitriptyline and, thus, all subjects were included in both arms (untreated versus treated) of the study.

The experiments were approved by the ethic committee of the University Hospital Essen under the number 20-9348-BO.

Primary cells
We obtained nasal epithelial cells from these volunteers immediately before oral administration of 0.5 mg/kg amitriptyline (Neuraxpharm, Germany) and again 1.5 h and 24 h after administration of amitriptyline. The cells were removed from the nasal mucosa by inserting a small brush into the nose (approximately 1.5-2 cm deep). The brush was gently rotated within the nose. Nasal epithelial cells were released from the brush and suspended immediately in 1 mL HEPES/saline (H/S; 132 mM NaCl, 20 mM HEPES [pH 7.4], 5 mM KCl, 1 mM CaCl₂, 0.7 mM MgCl₂, 0.8 mM MgSO₄) and immediately used for infection.

Cell lines
Vero cells (ATCC CCL-81; monkey kidney epithelial cells) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10 mM HEPES (pH 7.4; Carl Roth GmbH, Karlsruhe, Germany), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 μM...
nonessential amino acids, 100 U/mL penicillin, 100 μg/mL streptomycin (all from Invitrogen, city, country), and 10% FCS (PAA Laboratories GmbH, Coelbe, Germany).

Caco-2 colon epithelial cells (ATCC HTB-37) were cultured in DMEM supplemented as described above.

**METHOD DETAILS**

**Pseudoviral particles**

Pseudotyped viral particles based on a replication-deficient VSV that codes for eGFP and firefly luciferase instead of parental VSV-G (VSV*G-FLuc), were generated according to a previously published protocol. At 24 h after transfection by the calcium-phosphate method, HEK293T cells transiently expressing either SARS-2-S or VSV-G were inoculated with VSV-G-trans-complemented VSV*ΔG-FLuc for 1 h at 37°C and 5% CO₂, after which the inoculum was removed and cells were washed with phosphate-buffered saline (PBS). Finally, the cells were transferred to fresh culture medium and were incubated at 37°C and 5% CO₂. For cells expressing SARS-2-S, the culture medium was supplemented with anti-VSV-G antibody (I1, mouse hybridoma supernatant from American Type Culture Collection [ATCC] CRL-2700) for inactivation of residual VSV-G-trans-complemented VSV*ΔG-FLuc. At 16 h after inoculation, the culture supernatants were harvested, and cellular debris was pelleted by centrifugation (4,000 × g, 4°C, 10 min). The clarified supernatants were used for the experiments.

**Infection of nasal epithelial cells**

For infection freshly isolated nasal epithelial cells were pelleted by centrifugation, and resuspended in minimum essential medium (MEM) supplemented with 10% fetal calf serum (FCS) containing pp-VSV-SARS-CoV-2 spike particles. Cells were infected for 60 min, washed in H/S, and cultured for 24 h to allow expression of the eGFP encoded by the particles. Infection was analyzed with a Leica TCS SL confocal microscope (Mannheim, Germany) by counting the percentage of eGFP-positive epithelial cells in at least 500 epithelial cells per sample in randomly chosen microscopic fields.

A further aliquot of the nasal epithelial cells was immediately shock frozen in liquid nitrogen after removal for determination of acid sphingomyelinase activity (see below).

**Ex vivo treatment of nasal epithelial cells**

Nasal epithelial cells were also obtained from untreated volunteers as described above and were treated with 10 μM amitriptyline (Sigma; # A 8404) dissolved in 0.9% NaCl, anti-ceramide or control antibodies, neutral ceramidase (see below) or left untreated for 60 min **ex vivo** and then infected with pp-VSV-SARS-CoV-2 spike particles for 60 min. Cells were then washed and further incubated for 24 h to allow expression of eGFP. Infection was analyzed as above.

**Infection of Vero lines**

Vero cells were grown to subconfluence for 24 h on glass coverslips in a 24-well plate before measurement of the uptake of the pp-VSV-SARS-CoV-2 spike or pp-VSV-G particles. Amitriptyline (5, 10, 20, or 25 μM) was dissolved in 0.9% NaCl and added to the cells 4 h before the addition of pp-VSV-SARS-CoV-2 spike or pp-VSV-G particles. Because amitriptyline binds to serum proteins, we reduced the concentration of FCS in the medium to 1% during the 4 h preincubation period. Controls were also incubated in serum-reduced medium, but without amitriptyline. The medium was then removed, 250 μL of a cell culture supernatant containing pp-VSV-SARS-CoV-2 or pp-VSV-G particles and, if indicated, amitriptyline (5, 10, 20 or 25 μM) was added, and the cells were incubated for 8 h. In addition, we added 2 μg/mL anti-spike (S1) antibody (Sino Biological, #40150-R-007) or 2 μg/mL recombinant ACE2 (Abcam; # ab273687) to the cells 30 min before adding the viral particles. The concentrations were maintained during the infection. We then removed the supernatants, added DMEM medium supplemented as above, and incubated the cells for an additional 12 h to allow expression of eGFP. The medium was removed; cells were washed once in H/S, fixed in 1% paraformaldehyde (PFA) buffered with PBS (pH 7.3) for 10 min, washed, embedded in Mowiol, and analyzed with a Leica TCS-SL confocal microscope equipped with a 40 × lens and Leica LCS software version 2.61. We counted EGFP-positive cells in 2000 cells per sample in random chosen microscopic fields. In addition, fixed cells were stained with propidium iodide (0.5 μg/mL) for 2 min to visualize cells.

**Flow cytometry of surface ACE2 as measurement for infection**

Cells were cultured in 24-well plates, treated with 25 μM amitriptyline or solvent (0.9% NaCl) for 4 h or left untreated, infected with pp-VSV-SARS-CoV-2, pp-VSV or pp-VSV-G particles, the medium was removed and cells were collected with a cell dissociation buffer (GIBCO; #13151-014). Samples were washed twice in H/S, stained at 4°C for 45 min with 1 μg/mL anti-ACE2 antibodies (1:1000, R&D, #AF933) ceramicide antibodies, washed twice in ice-cold H/S, stained with FITC-coupled donkey anti-goat antibodies (1:1000; Jackson ImmunoResearch; #705-096-147) for 45 min at 4°C, washed and analyzed by flow cytometry with a BD Calibur.

**Infection with SARS-CoV-2**

Approximately 10⁶ Caco-2 colon epithelial cells (ATCC HTB-37) were cultured in 6-well plates in DMEM supplemented and pre-treated with amitriptyline or were left untreated in DMEM with 1% FCS for 4 h, as described above. Cells were then infected with 1000 plaque-forming units (PFU) of SARS-CoV-2 (isolate Muc-IMB-1, obtained from the Bundeswehr Institute of Microbiology,
Munich, Germany) in 1 mL medium for 1.5 h at 37°C, corresponding to a multiplicity of infection (MOI) of 0.001. Cells were then washed with DMEM and further incubated with 2.5 mL DMEM, 1% FCS, and 20 mM HEPES (pH 7.4) containing 10 μM or 25 μM amitriptyline or left untreated. Viral titers in the culture supernatants were determined after 24 h with plaque assays. Studies using RT-qPCR for quantification of the infection followed the same protocol, except that the MOI was increased to 0.1. The primer pairs used for RT-qPCR were purchased from Merck: SYBR Green 1, fwd-GCCTTCTCTCGTCTCATC and rev- AGCAGCATC ACCGCCATAG; and SYBR Green 2, fwd- AGCCTTCTCGTCTCTCATC and rev- CGGCCATTGCCAGCCATTC. The results were reproduced by two independent co-authors of the manuscript.

Neutralization of ceramide
To neutralize ceramide in Vero cells or nasal epithelial cells, we added 50 or 100 μg/mL of the anti-ceramide IgM antibody clone S85-9 (Glycobiotech; MAB_0014) or of a mouse monoclonal anti-ceramide IgG (Antibody Res. Corp.; #111583), or either 0.1 or 0.2 units/mL of neutral ceramidase (R&D, #3557 AH) to the cells, which were then immediately infected with pp-VSV-SARS-CoV-2 spike particles for 60 min. Controls were incubated with irrelevant IgM or IgG antibodies (Dako). Cells were then washed, cultured for 24 h, and analyzed for infection as above.

FITC-Annexin V binding
Cells were treated for 4 h with 10 or 25 μM amitriptyline in DMEM supplemented with 1% FCS as above. Incubation was then continued for 20 h in DMEM containing 10% FCS. Cells were trypsinized, washed in H/S, stained for 15 min with FITC-Annexin V (Roche), and analyzed by flow cytometry. Controls were permeabilized for 5 min with 0.1% Triton X-100 at room temperature before incubation with FITC-Annexin V.

TUNEL studies
Vero cells were treated with 10 or 25 μM amitriptyline as described for FITC-Annexin V staining. Cells were trypsinized, washed with PBS, fixed in 4% PFA buffered in PBS (pH 7.4) for 10 min, washed in PBS, permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 5 min at room temperature, and washed. Next, the TUNEL reaction was performed exactly as instructed by the vendor (Roche, #12156792910) using recombinant terminal deoxynucleotidyl transferase (rTdT; EC 2.7.7.31) and tetramethyl rhodamine (TMR) red-labeled nucleotides. Samples were analyzed by flow cytometry. Positive controls were incubated with recombinant micrococal nuclease or DNase I (3000 U/ml) for 10 min at 22°C before the TUNEL reaction.

Actin staining
Vero cells were grown on glass coverslips, treated with 10 or 25 μM amitriptyline as described above, washed, fixed for 10 min in 1% PFA buffered in PBS (pH 7.3), washed, permeabilized for 5 min with 0.1% Triton X-100 at room temperature, washed and stained with FITC-Phalloidin for 12 h at 4°C. The samples were washed again and embedded in Mowiol. Cells were then analyzed by confocal microscopy on a Leica TCS SL confocal microscope equipped with a 40 x lens and Leica LCS software version 2.61.

Genetic downregulation of sphingomyelinase
The expression of acid or neutral sphingomyelinase in Caco-2 cells was downregulated by transfection with commercial shRNA targeting acid sphingomyelinase (Santa Cruz Inc.; # sc-41650-SH) or neutral sphingomyelinase (Santa Cruz Inc.; # sc-62655-SH). Cells were transiently transfected with an irrelevant shRNA (Santa Cruz Inc.; # sc-108060). Dead cells were removed by Ficoll gradient centrifugation, and cells were cultured for 36 h before infection with pp-VSV-SARS-CoV-2 spike. Downregulation of acid or neutral sphingomyelinase was confirmed by measuring the activity of the enzyme in transfected, control-transfected, and untransfected cells.

Acid sphingomyelinase activity
To determine acid sphingomyelinase activity, we grew Vero or Caco-2 cells in 24-well plates. Cells were pretreated with amitriptyline for 4 h or transfected as above or were left untreated. The cells were washed in H/S and infected with 250 μL of cell culture supernatant containing pp-VSV-SARS-CoV-2 spike or control pp-VSV particles for 10 to 45 min. Untreated cells were incubated with DMEM that was supplemented as above. Amitriptyline was added at 5 - 25 μM as above. The incubation was terminated by removing the supernatants, and the cells were immediately lysed in 250 mM sodium acetate (pH 5.0) and 1% NP40 for 5 min. The lysates were removed from the plates and diluted to 0.2% NP40 in 250 mM sodium acetate (pH 5.0). Next, we added 0.05 μCi [14C]phosphorylcholine (52 mCi/mmol; Perkin Elmer, #NEC 663010UC) per sample. The substrate [14C]phosphorylcholine was dried for 10 min in a SpeedVac, resuspended in 250 mM sodium acetate (pH 5.0) and 0.1% NP40, and sonicated for 10 min in a bath sonicator before it was added to the samples. The samples were incubated for 30 min at 37°C with shaking at 300 rpm. The enzymatic reaction was terminated by extraction in 4 volumes of CHCl3:CH3OH (2:1, v/v), the samples were centrifuged, and an aliquot of the upper aqueous phase was scintillation-counted to determine the release of [14C]phosphorylcholine from [14C]phosphorylcholine.

To determine the effect of amitriptyline on the activity of the acid sphingomyelinase in nasal epithelial cells, we washed the cells once in H/S after infection. Pellets were immediately shock-frozen, lysed in 250 mM sodium acetate (pH 5.0) and 1% NP40 for 5 min, and processed as above.
Neutral sphingomyelinase activity
Vero cells were infected with pp-VSV-SARS-CoV-2 spike for 5, 10, 20, 30, 45, or 60 min or were left untreated; lysed in a buffer containing 100 mM TrisHCl (pH 7.4), 5 mM MgCl₂, 2.5 mM DTT, 0.2% Triton and 10 μg/ml each of aprotinin and leupeptin; sonicated; and incubated with 0.02 μCi [3H]sphingomyelin per sample for 30 min at 37°C. Samples were processed as described for acid sphingomyelinase.

Measurement of ceramide
Cells were treated as above with 25 μM amitriptyline for 4 h or left untreated and then washed in H/S. Next, 250 μL of the cell culture supernatant containing pp-VSV-SARS-CoV-2 spike or control pp-VSV or pp-VSV-G particles was added as above for a period of 10 to 45 min. Amitriptyline (25 μM) was immediately added again after the addition of the pseudoviral particles. Untreated cells were incubated with DMEM supplemented as above. The medium was removed, and cells were lysed in 200 μL H₂O, scraped from the plates, and extracted in CHCl₃:CH₃OH:1N HCl (100:100:1, v/v/v). Samples were centrifuged for 5 min at 14,000 rpm. The lower phase was collected, dried, and resuspended in 20 μL of a detergent solution (7.5% [w/v] n-octyl glucopyranoside, 5 mM cardiolipin in 1 mM diethylenetriaminepentaaetic acid [DTPA]). Micelles were obtained by bath sonication for 10 min and used for the kinase reaction, which was initiated by adding 70 μL of a reaction mixture containing 10 μL diacylglycerol (DAG) kinase (GE Healthcare Europe, Munich, Germany), 0.1 M imidazole/HCl (pH 6.6), 0.2 mM DTPA (pH 6.6), 70 mM NaCl, 17 mM MgCl₂, 1.4 mM ethylene glycol tetraacetic acid, 2 mM dithiothreitol, 1 μM adenosine triphosphate (ATP), and 5 μCi [32P]γATP (6000 Ci/mmol; Hartmann Radiochemicals, Braunschweig, Germany). The kinase reaction was performed for 60 min at room temperature with 300 rpm shaking and was terminated by the addition of 1 mL CHCl₃:CH₃OH:1N HCl (100:100:1, v/v/v), 170 μL buffered saline solution (135 mM NaCl, 1.5 mM CaCl₂, 0.5 mM MgCl₂, 5.6 mM glucose, 10 mM HEPES [pH 7.2]), and 30 μL of a 100 mM EDTA solution. Phases were separated, and the lower phase was collected. The samples were then dried in a SpeedVac, separated on Silica G60 thin-layer chromatography (TLC) plates with chloroform/acetone/methanol/acetic acid/H₂O (50:20:15:10:5, v/v/v/v/v), and developed with a Fuji phosphoimager. Ceramide amounts were determined by comparison with a standard curve using C16 to C24 ceramides as substrates.

Other antidepressants
To test the effects of other antidepressants on the infection of Vero cells with pp-VSV-SARS-CoV-2 spike or pp-VSV-G, we treated Vero cells for 4 h with 20 μM imipramine (Sigma-Aldrich; # I 0899), 10 or 20 μM desipramine (Sigma-Aldrich, # D 3900), 5 μM sertraline (Sigma-Aldrich; # S 6319), 10 or 20 μM escitalopram (Sigma-Aldrich; # E 4786), 10 or 20 μM maprotiline (Sigma-Aldrich; # M 9651) or 25 or 35 μM fluoxetine (Sigma-Aldrich; # M 9651) or 25 or 35 μM fluoxetine (Sigma-Aldrich; # M 9651). Amitriptyline, desipramine and imipramine, were dissolved in 0.9% NaCl, all other antidepressants in DMSO with a final concentration of 0.1% DMSO. Controls were 0.9% NaCl or 0.1% DMSO. We then determined the activity of acid sphingomyelinase or infected the cells with pp-VSV-SARS-CoV-2 spike or pp-VSV-G particles for 24 h and then determined the expression of eGFP or the expression of ACE2 on the cell surface as measurements for infection as above.

Ceramide reconstitution
Cells were treated with 10 or 20 μM amitriptyline, 10 or 20 μM imipramine, 10 or 20 μM desipramine, 5 μM sertraline, 10 or 20 μM escitalopram, or 10 or 20 μM maprotiline or 25 or 35 μM fluoxetine for 4 h or transfected with shRNA targeting the acid sphingomyelinase as above and infected with pp-VSV-SARS-CoV-2 spike, after which 10 μM C16 ceramide (Avanti Polar Lipids; # 860516) or 0.2 U/mL recombinant acid sphingomyelinas (specific activity: 1700 pmol/min/μg; R&D, #5348-PD-010) was immediately added. C16 ceramide was resuspended in cell culture medium and sonicated for 10 min in a bath sonicator before use. We then determined viral uptake as above.

Flow cytometry of surface ceramide
Vero cells were cultured in 48-well plates, treated with 25 μM amitriptyline or solvent (0.9% NaCl) for 4 h as above, each 2 μg/mL recombinant ACE2 or anti-spike antibodies or left untreated, and infected with pp-VSV-SARS-CoV-2, pp-VSV or pp-VSV-G particles for 30 min. The cells were collected with a cell dissociation buffer (GIBCO; #13151-014), washed twice in H/S, stained at 4°C for 45 min with 1 μg/mL anti-ceramide antibodies, clone S85-9, washed twice in ice-cold H/S, stained with Cy3-coupled donkey anti-mouse IgM F(ab)₂ fragments (1:1000; Jackson Immunoresearch; #715-166-020) for 45 min at 4°C, washed and analyzed by flow cytometry with a BD Calibur.

QUANTIFICATION AND STATISTICAL ANALYSIS
Data are expressed as arithmetic means ± SD. For the comparison of continuous variables from independent groups we used one-way ANOVA followed by post hoc Student’s t tests for all pairwise comparisons and the Bonferroni correction for multiple testing. The p values for the pairwise comparisons were calculated after Bonferroni correction. All values were normally distributed. Statistical significance was set at the level of p ≤ 0.05 (two-tailed). Sample size planning for the continuous variable in vivo experiments was based on two-sided Wilcoxon-Mann-Whitney tests (free software: G*Power Version 3.1.7, University of Duesseldorf, Germany). Investigators were blinded to the identity of the samples in all microscopy experiments.
DATA AVAILABILITY STATEMENTS

All data are available upon request from the authors. Authors confirm that all data are included in the manuscript.

ADDITIONAL RESOURCES

n/a